Association between Polymorphisms in Vascular Endothelial Growth Factor Gene and Response to Chemotherapies in Colorectal Cancer: A Meta-Analysis

Lei Wang*, Shan Ji*, Zeneng Cheng*

Research Institute of Drug Metabolism and Pharmacokinetics, School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, China

☯ These authors contributed equally to this work.
* chengzn@csu.edu.cn

Abstract

Background
Some studies have investigated the effects of polymorphisms in the vascular endothelial growth factor (VEGF) gene on responsiveness to chemotherapy for colorectal cancer (CRC) and have shown inconclusive results.

Methods
Eligible studies that assessed the associations between polymorphisms in the VEGF gene and response to chemotherapy in CRC were searched in the PubMed, Embase and Medline databases until November 2014. Odds ratios (OR) and 95% confidence intervals (CIs) were used to evaluate the associations, using Review Manager software, version 5.3. Stratified analysis was also conducted.

Results
In the overall analysis, a significant association with responsiveness to chemotherapy in CRC was identified in CC vs. CA of the VEGF -2578 C/A polymorphism (OR = 1.40, 95% CI 1.00-1.97, P = 0.05) and in CC+CT vs. TT of the VEGF -460 C/T polymorphism (OR = 0.71, 95% CI 0.53-0.96, P = 0.02). In subgroup analysis, a significant association was found in excluding anti-angiogenic agent subgroup in three comparison models of the VEGF -2578 C/A polymorphism and another three genetic models of the VEGF -460 C/T C/A polymorphism.

Conclusions
CC vs. CA of the VEGF -2578 C/A polymorphism and CC+CT vs. TT of the VEGF -460 C/T polymorphism might be predictive factors of responsiveness to chemotherapy in CRC. However, single-nucleotide polymorphisms in the VEGF gene lacked sufficient predictive
ability to determine whether patients with CRC should add anti-angiogenic agents to their chemotherapy regimens.

Introduction

Colorectal cancer (CRC) is one of the leading causes of death worldwide, and approximately 1 million people are diagnosed with CRC every year [1–2]. It is an enormous challenge to determine the appropriate treatment to improve the poor prognosis of CRC, and the median survival in patients remains less than initially desired [3].

Currently, chemotherapy is widely used in malignant tumors for significant improvements in overall survival (OS) and progression free survival (PFS) in patients [4–5]. Regarding CRC, XELOX (capecitabine + oxaliplatin), FOLFIRI (fluorouracil + leucovorin + irinotecan) and FOLFOX-4 (fluorouracil + leucovorin + oxaliplatin) are all first-line chemotherapy regimens in clinical practice [6]. Recently, new biological therapies employing anti-angiogenic agents, including inhibitors of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR), have been combined with the existing chemotherapy regimens [7–8]. The addition of anti-angiogenic agents to first-line chemotherapy regimens has shown efficacy in CRC by significantly prolonging PFS and OS [9]. However, there have been inter-individual differences in the clinical outcomes of patients receiving chemotherapy for CRC. A reliable marker contributes to improving therapeutic outcomes and limiting potential adverse events through identifying patients who will benefit from these therapies.

The VEGF gene is located on chromosome 6p21.3, and its coding region spans approximately 14 kilobases and consists of 8 exons [10–11]. The VEGF gene is highly polymorphic, and numerous single nucleotide polymorphisms (SNPs) have been found in its promoter and 5′-, and 3′- untranslated regions (UTR). VEGF -2578 C/A (rs699947), -460C/T (rs3025039), +405G/C (rs2010963), and +936C/T (rs833061) were the most common SNPs in the VEGF gene, where -2578 C/A and -460C/T were in the promoter, +405G/C was in the 5′- UTR, and +936C/T was in the 3′- UTR. These SNPs have been reported to be associated with variations in VEGF protein production. For example, VEGF -460C/T influences VEGF protein translation efficiency, and VEGF +936C/T affects VEGF expression in tumor tissue [12–13].

CRC is a complicated disease affected by both genetic polymorphisms and environmental factors [14–15]. VEGF gene polymorphisms have been reported to be associated with CRC through regulation of the expression of VEGF, which has been identified as playing a key role in a series of pathologic processes involved in tumor growth and metastasis. Moreover, VEGF-involved angiogenesis pathways are also important targets of chemotherapeutic treatment in CRC [16]. Therefore, VEGF gene polymorphisms have been suggested to influence the response to chemotherapy in CRC, and they might be of great value as potential biomarkers to predict clinical outcomes.

SNPs in the VEGF gene, including -2578 C/A, -460C/T, +405G/C, and +936C/T, have been focused in the relationship of the gene with the response to chemotherapy in CRC [17–24]. However, these studies showed inconclusive results, probably because the sample size included in any single study was so small that it lacked inadequate evidence to demonstrate a comprehensive conclusion. In contrast, meta-analysis is a powerful method for synthesizing information from varied investigations on the same issue [25]. Therefore, a meta-analysis of all eligible studies could provide reliable information about the associations between VEGF polymorphisms and response to chemotherapy in CRC.
In our work, a meta-analysis of all published studies was performed to investigate whether VEGF polymorphisms were associated with responsiveness to chemotherapy in patients with CRC. Moreover, a subgroup analysis with regard to a combination of anti-angiogenic agents in chemotherapy regimens was also performed, to investigate whether SNPs in the VEGF gene could work as biomarkers to predict the outcomes of adding anti-angiogenic agents to chemotherapies for CRC. As far as we know, this was the first systemic review and meta-analysis that focused on the associations between VEGF gene polymorphisms and response to chemotherapy for CRC.

**Methods**

**Literature search**

All studies assessing the associations between polymorphisms in the VEGF gene and response to chemotherapy in CRC were retrieved via an exhaust search of databases, including PubMed, Embase and Medline. The bibliographic search was performed by two investigators using the following retrieval terms: ("vascular endothelial growth factor a"[MeSH Terms] OR "vascular endothelial growth factor a"[All Fields] OR "vegf"[All Fields]) AND ("polymorphism, genetic"[MeSH Terms] OR ("polymorphism"[All Fields] AND "genetic"[All Fields]) OR "genetic polymorphism"[All Fields] OR "polymorphism"[All Fields])) AND (response[All Fields] OR (clinical[All Fields] AND outcome[All Fields])) AND ("colorectal neoplasms"[MeSH Terms] OR ("colorectal"[All Fields] AND "neoplasms"[All Fields]) OR "colorectal neoplasms"[All Fields] OR ("colorectal"[All Fields] AND "cancer"[All Fields]) OR "colorectal cancer"[All Fields]).

Other potentially eligible studies were found by manually searching relevant reviews and the included studies. All of the records were updated to November 2014. Only English-language articles were used for this meta-analysis.

**Inclusion and exclusion criteria**

For inclusion in the meta-analysis, studies had to meet the following criteria: (1) studies assessing the associations between polymorphisms in the VEGF gene and response to chemotherapy in CRC; (2) independent prospective or retrospective association studies; and (3) studies providing detailed data to estimate odds ratios (ORs) and corresponding 95% confidence intervals (CIs). Studies were excluded if they were other types of original studies, such as reviews, meta-analyses and case reports. Moreover, studies were also not eligible for this meta-analysis if they lacked critical information.

**Data extraction**

The data extraction was conducted independently by two investigators (L. Wang and S. Ji). Inter-researcher discrepancies were settled by discussion or by a third reviewer (Z. N. Cheng). The following critical data were extracted from each eligible study: first author, publication year, ethnicity, number of patients, median age, variation category, treatment modality, response criteria and genotype data.

**Statistical analysis**

ORs and 95% CIs were used to evaluate the associations of VEGF gene polymorphisms with response to chemotherapy in CRC, using Review Manager software, version 5.3 (provided by the Cochrane Collaboration), and statistical significance of the OR was ascertained with a P value from the Z-test less than 0.05. Six contrasts for the VEGF -2578 C/A polymorphism were evaluated: comparison of the A allele with C allele; comparison of CC+CA vs. AA; comparison of CC+CA vs. AA; comparison of
CC vs. CA+AA; comparison of CC vs. AA; comparison of CC vs. CA; and comparison of CA vs. AA. An evaluation of similar comparison models was also performed in the other three VEGF gene polymorphisms, including VEGF -460 C/T, VEGF +405 G/C and VEGF +936 C/T. Applicability to the effects models depended on the degree of between-study heterogeneity, which was estimated by Cochran’s Q test and the I² test in this meta-analysis. The heterogeneity across studies was identified by a significant Q test (P < 0.10) or by I² > 50%; thus, the random effects model was selected for the evaluation of each investigation with combined ORs. In contrast, the fixed effects model was used for P > 0.10 from Q test or for I² < 50%. Subgroup analysis was undertaken of combinations of anti-angiogenic agents in chemotherapy regimens.

To evaluate the stability of the outcomes, sequential exclusion of individual studies was performed in the sensitivity analysis [26]. The effect of potential publication bias was assessed with both visual assessment of Begg’s funnel plot and Egger’s test [27]. Two sided P-values were used for statistical decisions in this meta-analysis, and statistical significance was considered when the P-value was less than 0.05.

**Results**

**Study characteristics**

A total of 35 relevant studies were retrieved from an initial search of the PubMed, Embase and Medline databases. After removing duplicates and reviews, 18 full-text articles were assessed for eligibility. Finally, 7 studies met the inclusion criteria and were included in the meta-analysis [17–23]. Study selection is illustrated in Fig 1.

The characteristics of the selected studies are listed in Table 1. All 7 studies, involving a total of 1184 patients, were included in the meta-analysis, including 4 studies of the VEGF -2578 C/T polymorphism, 5 studies of VEGF -460 C/T, 3 studies of VEGF +405 G/C, and 5 studies of VEGF +936 C/T. The publication years of all of the selected studies ranged from 2006 to 2013.

**Association of the VEGF -2578 C/A polymorphism with response to chemotherapy in CRC**

A total of 4 studies were included in the meta-analysis. In overall analysis, between-study heterogeneity was apparent in the comparison models of CA vs. AA (I² = 75%, P_heterogeneity = 0.02), so a random-effects model was used. However, no evidence of heterogeneity was found in the other five comparison models of the C allele vs. A allele (I² = 0%, P_heterogeneity = 0.41), CC vs. CA+AA (I² = 17%, P_heterogeneity = 0.30), CC+CA vs. AA (I² = 50%, P_heterogeneity = 0.11), CC vs. AA (I² = 0%, P_heterogeneity = 0.49), or CC vs. CA (I² = 64%, P_heterogeneity = 0.06), so the fixed-effects model was applied for those genetic models (Table 2). A significant association between the VEGF -2578 C/A polymorphism and responsiveness to chemotherapy was found in the comparison model of CC vs. CA (OR = 1.40, 95% CI 1.00–1.97, P = 0.05) (Fig 2A). Moreover, in the subgroup of excluding anti-angiogenic agents, a significant association with responsiveness to chemotherapy was found in three comparison models, including CC+CA vs. AA (OR = 0.38, 95% CI 0.15–0.95, P = 0.04), CC vs. CA (OR = 5.12, 95% CI 1.61–16.31, P = 0.006) (Fig 3) and CA vs. AA (OR = 0.20, 95% CI 0.07–0.59, P = 0.004) (Table 3).

**Association of the VEGF -460 C/T polymorphism with response to chemotherapy in CRC**

Five studies were finally included in the meta-analysis. There was no apparent between-study heterogeneity found among the six genetic models, so fixed-effects models were used for all of them (Table 2). In the overall analysis, the VEGF -460 C/T polymorphism was found to be
associated with responsiveness to chemotherapy in the comparison model of CC+CT vs. TT (OR = 0.71, 95% CI 0.53–0.96, P = 0.02) (Fig 2B). Moreover, similar results were obtained in the subgroup analysis (Table 3). In the subgroup of excluding anti-angiogenic agents, a significant association between the VEGF -460 C/A polymorphism with responsiveness to chemotherapy was identified in three comparison models, including CC+CT vs. TT (OR = 0.47, 95% CI 0.26–0.85, P = 0.01) (Fig 4), CC vs. CT (OR = 3.22, 95% CI 1.14–9.03, P = 0.03), and CT vs. TT (OR = 0.32, 95% CI 0.10–0.97, P = 0.04).

**Association of the VEGF +405 G/C polymorphism with response to chemotherapy in CRC**

This meta-analysis included 5 eligible studies of the association of the VEGF +405 G/C polymorphism with response to chemotherapy in CRC. Due to between-study heterogeneity was found in the three associated comparison models of the G allele vs. C allele (I² = 81%, P heterogeneity = 0.02), GG vs. GC+CC (I² = 71%, P heterogeneity = 0.03), and GG vs. GC (I² = 81%, P heterogeneity = 0.02), random-effects models were utilized. The remaining genetic models all used fixed-effects models. In the overall analysis, no significant associations were found in any of the comparison models including the G allele vs. the C allele (OR = 1.12, 95% CI 0.46–2.73, P = 0.81), GG vs. GC+CC.
Association of the VEGF +936 C/T polymorphism and response to chemotherapy in CRC

A total of 4 studies were included in this meta-analysis. The effects model was finally selected as the fixed-effects model for all six comparison models, mainly because no between-study heterogeneity was found in these genetic models. No significant associations between the VEGF +936 C/T polymorphism and response to chemotherapy in CRC were identified in any comparison models, including C allele vs. T allele (OR = 1.01, 95% CI 0.50–2.07, P = 0.97), GG vs. CC (OR = 0.77, 95% CI 0.38–1.57, P = 0.47), GG vs. GC (OR = 0.81, 95% CI 0.39–1.70, P = 0.58), GC vs. CC (OR = 1.36, 95% CI 0.38–4.86, P = 0.63), or GC vs. CC (OR = 0.72, 95% CI 0.33–1.57, P = 0.41) (Table 2). In addition, similar results were obtained in the subgroup analysis, with no associations identified in either subgroup including or excluding anti-angiogenic agents (Table 3).

Sensitivity analysis and publication bias

Individual studies were consecutively excluded in the sensitivity analysis to investigate whether the obtained results were robust. The analysis showed that the results obtained in the meta-analysis were statistically robust, because the corresponding combined ORs in all of the separate subgroup analyses were relatively stable when deleting any individual study. Publication bias was also evaluated using funnel plots and Egger’s test.
bias was evaluated with both visual assessment of Begg’s funnel plot and Egger’s test in the meta-analysis. As illustrated in Fig 5, symmetrical funnel plots indicated that there was no evidence of publication bias for the meta-analysis, and the results of Begg’s test also resulted in the same conclusion (detailed data not show).

### Discussion

Some published studies have reported inconclusive results about the associations between polymorphisms in the VEGF gene and response to chemotherapy in CRC, probably due to limited predictive ability with relatively small sample sizes. For this reason, a meta-analysis was performed to obtain a comprehensive conclusion on the basis of pooled data from all 7 eligible studies. In this meta-analysis, 4 common SNPs in the VEGF gene were systematically investigated for their associations with response to chemotherapy in CRC. As described in Table 2, significant association were found in the CC vs. CA model of the VEGF -2578 C/A polymorphism and the CC+CT vs. TT model of the VEGF -460 C/T polymorphism. However, no significant associations were identified in other models of these two polymorphisms, and similar results were encountered in all of the comparison models of the VEGF +405 G/C and VEGF +936 C/T polymorphisms. Although the number of relevant studies included in the separate

| Polymorphism | Comparison model | Test of heterogeneity | Effects model | Test of association |
|--------------|------------------|-----------------------|---------------|--------------------|
| VEGF -2578 C/A | C vs. A | 0% | 0.41 | Fixed model | 1.12 | 0.91–1.38 | 0.29 |
| | CC vs. CA+AA | 17% | 0.30 | Fixed model | 1.34 | 0.97–1.83 | 0.07 |
| | CC+CA vs. AA | 50% | 0.11 | Fixed model | 1.01 | 0.74–1.38 | 0.96 |
| | CC vs. AA | 0% | 0.49 | Fixed model | 1.24 | 0.82–1.86 | 0.31 |
| | CC vs. CA | 64% | 0.06 | Fixed model | 1.40 | 1.00–1.97 | 0.05 |
| | CA vs. AA | 75% | 0.02 | Random model | 0.68 | 0.29–1.57 | 0.37 |
| VEGF -460 C/T | C vs. T | 0% | 0.44 | Fixed model | 0.90 | 0.73–1.11 | 0.33 |
| | CC vs. CT+TT | 23% | 0.27 | Fixed model | 1.02 | 0.75–1.41 | 0.88 |
| | CC+CT vs. TT | 6% | 0.36 | Fixed model | 0.71 | 0.53–0.96 | 0.02 |
| | CC vs. TT | 0% | 0.51 | Fixed model | 0.82 | 0.55–1.24 | 0.35 |
| | CC vs. CT | 60% | 0.08 | Fixed model | 1.14 | 0.78–1.67 | 0.49 |
| | CT vs. TT | 28% | 0.25 | Fixed model | 0.76 | 0.54–1.06 | 0.11 |
| VEGF +405 G/C | G vs. C | 81% | 0.02 | Random model | 1.12 | 0.46–2.73 | 0.81 |
| | GG vs. GC+CC | 71% | 0.03 | Random model | 1.01 | 0.50–2.07 | 0.97 |
| | GG+GC vs. CC | 0% | 0.37 | Fixed model | 0.77 | 0.38–1.57 | 0.47 |
| | GG vs. CC | 59% | 0.12 | Fixed model | 0.81 | 0.39–1.70 | 0.58 |
| | GG vs. GC | 81% | 0.02 | Random model | 1.36 | 0.38–4.86 | 0.63 |
| | GC vs. CC | 0% | 0.96 | Fixed model | 0.72 | 0.33–1.57 | 0.41 |
| VEGF +936 C/T | C vs. T | 0% | 0.62 | Fixed model | 0.81 | 0.56–1.17 | 0.26 |
| | CC vs. CT+TT | 0% | 0.90 | Fixed model | 0.76 | 0.54–1.09 | 0.13 |
| | CC+CT vs. TT | 0% | 0.49 | Fixed model | 0.94 | 0.31–2.91 | 0.92 |
| | CC vs. TT | 0% | 0.50 | Fixed model | 0.86 | 0.28–2.68 | 0.80 |
| | CC vs. CT | 0% | 0.85 | Fixed model | 0.74 | 0.48–1.16 | 0.19 |
| | CT vs. TT | 0% | 0.48 | Fixed model | 1.15 | 0.36–3.70 | 0.82 |

OR: odd ratio; CI: confidence interval.

doi:10.1371/journal.pone.0126619.t002
Fig 2. Meta-analysis of the VEGF -2578 C/A polymorphism (a) and VEGF -460 C/T polymorphism (b) with response to chemotherapies in colorectal cancer. (a) Analytical results of the genetic model of CC vs. CA in VEGF -2578 C/A polymorphism. (b) Results in the meta-analysis of the comparison model of CC+CT vs. TT in VEGF -460 C/T polymorphism.

doi:10.1371/journal.pone.0126619.g002

Fig 3. Subgroup analysis of the association between VEGF -2578 C/A polymorphisms with response to chemotherapies in colorectal cancer (CC vs. CA).

doi:10.1371/journal.pone.0126619.g003
analysis was not sufficiently large, valuable evidence was nevertheless provided by synthesizing all of the published data, proving that the CC vs. CA model of the VEGF -2578 C/A polymorphism and the CC+CT vs. TT model of the VEGF -460 C/T polymorphism might be predictive factors to responsiveness to chemotherapy in CRC.

Recently, new biological therapies employing anti-angiogenic agents, including EGFR and VEGF inhibitors, such as cetuximab and bevacizumab, respectively, have been combined with existing chemotherapy regimens because the optimal first-line treatment is no longer chemotherapy alone but a combination with new biological therapies [28]. Therefore, to investigate

| Polymorphism   | Comparison model | anti-angiogenic monoclonal antibody drugs | OR  | 95% CI     | P-value |
|----------------|------------------|------------------------------------------|-----|-----------|---------|
| VEGF -2578 C/A| C vs. A          | include                                  | 1.15| 0.92–1.43 | 0.22    |
|                |                  | exclude                                  | 0.92| 0.50–1.68 | 0.78    |
|                | CC vs. CA+AA     | include                                  | 1.25| 0.90–1.75 | 0.19    |
|                |                  | exclude                                  | 2.46| 0.92–6.55 | 0.07    |
|                | CC+CA vs. AA     | include                                  | 1.15| 0.82–1.62 | 0.41    |
|                |                  | exclude                                  | 0.38| 0.15–0.95 | 0.04    |
|                | CC vs. AA        | include                                  | 1.27| 0.82–1.98 | 0.28    |
|                |                  | exclude                                  | 1.03| 0.34–3.12 | 0.96    |
|                | CC vs. CA        | include                                  | 1.24| 0.87–1.78 | 0.23    |
|                |                  | exclude                                  | 5.12| 1.61–16.31| 0.006   |
|                | CA vs. AA        | include                                  | 1.02| 0.67–1.54 | 0.94    |
|                |                  | exclude                                  | 0.20| 0.07–0.59 | 0.004   |
| VEGF -460 C/T  | C vs. T          | include                                  | 0.88| 0.70–1.10 | 0.25    |
|                |                  | exclude                                  | 1.09| 0.60–2.00 | 0.78    |
|                | CC vs. CT+TT     | include                                  | 0.93| 0.66–1.30 | 0.67    |
|                |                  | exclude                                  | 2.12| 0.85–5.27 | 0.11    |
|                | CC+CT vs. TT     | include                                  | 0.82| 0.58–1.14 | 0.24    |
|                |                  | exclude                                  | 0.47| 0.26–0.85 | 0.01    |
|                | CC vs. TT        | include                                  | 0.80| 0.51–1.24 | 0.31    |
|                |                  | exclude                                  | 1.02| 0.33–3.14 | 0.97    |
|                | CC vs. CT        | include                                  | 0.97| 0.64–1.46 | 0.89    |
|                |                  | exclude                                  | 3.22| 1.14–9.03 | 0.03    |
|                | CT vs. TT        | include                                  | 0.82| 0.58–1.18 | 0.29    |
|                |                  | exclude                                  | 0.32| 0.10–0.97 | 0.04    |
| VEGF +936 C/T  | C vs. T          | include                                  | 0.86| 0.56–1.32 | 0.49    |
|                |                  | exclude                                  | 0.66| 0.32–1.38 | 0.27    |
|                | CC vs. CT+TT     | include                                  | 0.80| 0.54–1.18 | 0.26    |
|                |                  | exclude                                  | 0.59| 0.24–1.42 | 0.24    |
|                | CC+CT vs. TT     | include                                  | 0.85| 0.23–3.13 | 0.81    |
|                |                  | exclude                                  | 1.28| 0.13–12.82| 0.83    |
|                | CC vs. TT        | include                                  | 0.81| 0.22–3.00 | 0.76    |
|                |                  | exclude                                  | 1.04| 0.10–10.69| 0.97    |
|                | CC vs. CT        | include                                  | 0.82| 0.49–1.36 | 0.43    |
|                |                  | exclude                                  | 0.55| 0.22–1.36 | 0.20    |
|                | CT vs. TT        | include                                  | 0.96| 0.24–3.75 | 0.95    |
|                |                  | exclude                                  | 1.89| 0.18–20.39| 0.60    |

OR: odd ratio; CI: confidence interval.

doi:10.1371/journal.pone.0126619.t003
whether SNPs of the VEGF gene will influence the responsiveness to chemotherapy of patients with CRC through a combination of anti-angiogenic agents, a subgroup analysis was performed subsequently of a combination of anti-angiogenic agents in chemotherapy strategies. Due to the lack of sufficient data to perform a meta-analysis accordingly, the association between the VEGF +405 G/C polymorphism and responsiveness to chemotherapy was not included in the subgroup analysis. On the basis of the results of the subgroup analysis, a significant association of excluding the anti-angiogenic agents subgroup was found in the comparison models of the VEGF -2578 C/A polymorphism, including the CC+CA vs. AA, CC vs. CA, and CA vs. AA models. Additionally, similar results were also obtained for the VEGF -460 C/A polymorphism. In the subgroup analysis, all positive conclusions arose from the subgroup of excluding the anti-angiogenic agents. No associations of VEGF polymorphisms with responsiveness to chemotherapy were found in the subgroup including anti-angiogenic agents, indicating that SNPs in the VEGF gene might have weak ability to predict the responsiveness to chemotherapy of CRC patients receiving anti-angiogenic agents, alone or in combination with other first-line chemotherapy regimens.

Moreover, a significant association with responsiveness to chemotherapy in CRC was identified in the CC vs. CA model of the VEGF -2578 C/A polymorphism and the CC+CT vs. TT model of the VEGF -460 C/T polymorphism. By undertaking subgroup analyses with regard to combinations of anti-angiogenic agents in chemotherapy strategies, we found that associations were only significant in the subgroups excluding anti-angiogenic agents, while negative results were shown in subgroups of including the anti-angiogenic agents (Figs 3 and 4). Therefore, the results indicated that the associations between VEGF polymorphisms and responsiveness to chemotherapy were not derived from receiving anti-angiogenic agents alone or by combining anti-angiogenic agents with other first-line chemotherapy regimens. In other words, although VEGF is a commonly used target of new biological therapies that aim to block the angiogenic

---

**Fig 4. Subgroup analysis of the association between VEGF -460 C/T polymorphisms with response to chemotherapies in colorectal cancer (CC +CT vs. TT).**

[Graph showing subgroup analysis results]
pathway, there was limited evidence that the SNPs in the VEGF gene lack sufficient predictive ability as biomarkers, only from the perspective of chemotherapeutic responsiveness, to identify whether patients with CRC should add anti-angiogenic agents to their chemotherapy regimens.

Although surprising but valuable information was initially obtained in this meta-analysis, this meta-analysis was nevertheless limited due to some deficiencies. First, the limited numbers of both the studies and subjects might have provided insufficient statistical power to evaluate the associations between VEGF polymorphisms and responsiveness to chemotherapy. Second, the heterogeneity of chemotherapeutic regimens might have affected the accuracy of the analysis results. Although the limited number of related studies made it difficult to perform a meta-analysis in the present study when stratified according to chemotherapeutic regimens, a more accurate stratification should be undertaken in the future on the basis of more related studies being published. Third, the sources of inter-study heterogeneity could not be addressed for most of the polymorphisms. Fourth, although there was no evident publication bias identified, potential bias might have distorted the results of the meta-analysis. Finally, relevant effects caused by other environmental factors were difficult to estimate due to publication limitations or incomplete raw data.

Fig 5. Funnel plots of studies included in the meta-analysis. (a) Funnel plot of the genetic model of CC vs. CT+TT in VEGF + 936 C/T polymorphism. (b) Funnel plot of the comparison model of CC vs. CA+AA in VEGF -2578 C/T polymorphism. (c) Funnel plot of the CC vs. CT+TT model in VEGF -460 C/T polymorphism. (d) Funnel plot of the GG+GC vs. CC model in VEGF +405 C/T polymorphism.
Although the above limitations existed, this initial meta-analysis of the association between VEGF polymorphisms and responsiveness to chemotherapy in CRC was statistically more persuading than any single study. It concluded that the CC vs. CA model of the VEGF -2578 C/A polymorphism and the CC+CT vs. TT model of the VEGF -460 C/T polymorphism might be predictive factors in responsiveness to chemotherapy in CRC. However, SNPs in the VEGF gene lack sufficient predictive ability as biomarkers to identify whether patients with CRC should add anti-angiogenic agents to their chemotherapy regimes. To assess more accurately the associations between VEGF polymorphisms and responsiveness to chemotherapy in CRC, further studies conducted in standardized and unbiased manner are required.

Supporting Information
S1 File. PRISMA Checklist. (DOC)
S2 File. Meta-analysis on Genetic Association Studies Checklist. (DOC)
S3 File. List of full-text excluded articles. (DOC)

Acknowledgments
We thank all our colleagues working in the Research Institute of Drug Metabolism and Pharmacokinetics, School of Pharmaceutical Sciences, Central South University.

Author Contributions
Conceived and designed the experiments: ZNC. Performed the experiments: LW SJ. Analyzed the data: LW SJ. Contributed reagents/materials/analysis tools: ZNC. Wrote the paper: LW.

References
1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA: a cancer journal for clinicians 55: 74–108. PMID: 15761078
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA: a cancer journal for clinicians 65: 87–108. doi: 10.3322/caac.21262 PMID: 25651787
3. Boyle P, Ferlay J (2005) Mortality and survival in breast and colorectal cancer. Nature Clinical Practice Oncology 2: 424–425. PMID: 16264992
4. Xenidis N, Perraki M, Apostolaki S, Agelaki S, Kalbakis K, Vardakis N, et al. (2013) Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer. British journal of cancer 108: 549–556. doi: 10.1038/bjc.2012.597 PMID: 23329233
5. Yoon DH, Ryu MH, Park YS, Lee HJ, Lee C, Ryoo BY, et al. (2012) Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. British journal of cancer 106: 1039–1044. doi: 10.1038/bjc.2012.47 PMID: 22343617
6. Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. (2011) XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. British journal of cancer 105: 58–64. doi: 10.1038/bjc.2011.201 PMID: 21673685
7. Martinelli E, Troiani T, Morgillo F, Orditura M, De Vita F, Belli G, et al. (2013) Emerging VEGF-receptor inhibitors for colorectal cancer. Expert opinion on emerging drugs 18: 25–37. doi: 10.1517/14728214.2013.749856 PMID: 23216053
8. Hansen TF, Jakobsen A (2011) Clinical implications of genetic variations in the VEGF system in relation to colorectal cancer. Pharmacogenomics 12: 1681–1693. doi: 10.2217/pgs.11.118 PMID: 22116052
9. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S, et al. (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. The Lancet Oncology 15: 1065–1075. doi: 10.1016/S1470-2045(14)70330-4 PMID: 25088940

10. Vincenti V, Cassano C, Rocchi M, Persico MG (1996) Assignment of the vascular endothelial growth factor gene to human chromosome 6p21. 3. Circulation 93: 1493–1495. PMID: 8608615

11. Brogan J, Khan N, Isaac K, Hutchinson JA, Pravica V, Hutchinson IV (1999) Novel polymorphisms in the promoter and 5′ UTR regions of the human vascular endothelial growth factor gene. Human immunology 60: 1245–1249. PMID: 10626738

12. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE (2000) Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12: 1232–1235. PMID: 10930302

13. Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Siviridis E (2004) VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 46: 293–298. PMID: 15541813

14. Hutter CM, Chang-Claude J, Slattery ML, Pflugeisen BM, Lin Y, Duggan D, et al. (2012) Characterization of gene–environment interactions for colorectal cancer susceptibility loci. Cancer research 72: 2036–2044. doi: 10.1158/0008-5472.CAN-11-4067 PMID: 22367214

15. Liu L, Zhong R, Wei S, Yin J, Xiang H, Zou L, et al. (2011) Interactions between genetic variants in the adiponectin, adiponectin receptor 1 and environmental factors on the risk of colorectal cancer. PLoS One 6: e27301. doi: 10.1371/journal.pone.0027301 PMID: 22087284

16. Sun W (2012) Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy. J Hematol Oncol 5: 63–72. doi: 10.1186/1758-8855-5-63 PMID: 23057939

17. Zhang W, Gordon M, Press OA, Rhodes K, Vallböhmer D, Yang DY, et al. (2006) Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenetics and genomics 16: 475–483. PMID: 16783830

18. Lurje G, Nagashima F, Zhang W, Yang D, Chang HM, Gordon MA, et al. (2008) Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clinical Cancer Research 14: 7884–7895. doi: 10.1158/1078-0432.CCR-07-5165 PMID: 19047118

19. Loupakis F, Cremolini C, Yang D, Salvatore L, Zhang W, Wakatsuki T, et al. (2013) Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. PLoS one 8: e66774. doi: 10.1371/journal.pone.0066774 PMID: 23861747

20. Koutras AK, Antonacopoulou AG, Eleftheraki AG, Dimitrakopoulos FI, Koumarianou A, Varthalitis I, et al. (2012) Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab. The pharmacogenomics journal 12: 468–475. doi: 10.1038/tpj.2011.37 PMID: 21844885

21. Chen MH, Tseng CH, Chen PM, Lin JK, Lin TC, Chen WS, et al. (2011) VEGF–460T→C polymorphism and its association with VEGF expression and outcome to FOLFOX-4 treatment in patients with colorectal carcinoma. The pharmacogenomics journal 11: 227–236. doi: 10.1038/tpj.2010.48 PMID: 20831372

22. Hansen TF, Spindler KG, Andersen RF, Lindebjerg J, Brandslund J, Jakobsen A (2010) The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer. The pharmacogenomics journal 11: 53–60. doi: 10.1038/tpj.2010.4 PMID: 20125120

23. Hansen TF, DePont Christensen R, Andersen RF, Spindler KG, Johnsson A, Jakobsen A (2012) The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer. International journal of colorectal disease 27: 715–720. doi: 10.1007/s00384-011-1382-6 PMID: 22139032

24. Sohn BS, Park SJ, Kim JE, Kim KP, Hong YS, Suh C, et al. (2014) Single-Nucleotide Polymorphisms in the Vascular Endothelial Growth Factor Pathway and Outcomes of Patients Treated with First-Line Cytotoxic Chemotherapy Combined with Bevacizumab for Advanced Colorectal Cancer. Oncology 87: 280–292. doi: 10.1159/000365593 PMID: 25139485

25. Greco T, Zangrillo A, Biondi-Zoccai G, Landoni G (2013) Meta-analysis: pitfalls and hints. Heart, lung and vessels 5: 219–225. PMID: 24364016

26. Chootrakool H, Shi JQ, Yue R (2011) Meta-analysis and sensitivity analysis for multi--arm trials with selection bias. Statistics in medicine 30: 1183–1198. doi: 10.1002/sim.4143 PMID: 21538449

27. Sterne JA, Egger M, Smith GD (2001) Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. BMJ: British Medical Journal 323: 101–105. PMID: 11451790
28. Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, et al. (2014) Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. New England Journal of Medicine 371: 1609–1618. doi: 10.1056/NEJMoa1403108 PMID: 25337750